Donna Curtis
Concepts (150)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza A Virus, H1N1 Subtype | 6 | 2016 | 149 | 0.910 |
Why?
| | Influenza Vaccines | 3 | 2016 | 537 | 0.750 |
Why?
| | Influenza, Human | 7 | 2016 | 618 | 0.670 |
Why?
| | Immunocompromised Host | 2 | 2019 | 202 | 0.580 |
Why?
| | Orthomyxoviridae | 2 | 2015 | 43 | 0.490 |
Why?
| | West Nile Fever | 1 | 2016 | 54 | 0.480 |
Why?
| | Virus Shedding | 1 | 2015 | 48 | 0.480 |
Why?
| | B-Lymphocyte Subsets | 1 | 2015 | 75 | 0.450 |
Why?
| | Antibodies, Viral | 2 | 2016 | 624 | 0.440 |
Why?
| | Vaccines, Attenuated | 3 | 2020 | 131 | 0.400 |
Why?
| | Vaccination | 5 | 2020 | 1377 | 0.400 |
Why?
| | HIV Infections | 2 | 2015 | 2828 | 0.340 |
Why?
| | Kidney Transplantation | 1 | 2016 | 701 | 0.310 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2021 | 614 | 0.300 |
Why?
| | Postoperative Complications | 2 | 2016 | 2639 | 0.270 |
Why?
| | Hemagglutination Inhibition Tests | 3 | 2016 | 38 | 0.270 |
Why?
| | Organ Transplantation | 2 | 2019 | 248 | 0.250 |
Why?
| | Cross Infection | 2 | 2019 | 250 | 0.240 |
Why?
| | Child | 19 | 2023 | 21819 | 0.230 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2017 | 234 | 0.220 |
Why?
| | Respiratory Tract Infections | 2 | 2022 | 394 | 0.220 |
Why?
| | Intensive Care Units | 3 | 2017 | 800 | 0.200 |
Why?
| | Staphylococcal Infections | 2 | 2017 | 399 | 0.190 |
Why?
| | Liver Transplantation | 2 | 2020 | 871 | 0.190 |
Why?
| | Child, Preschool | 9 | 2019 | 10997 | 0.190 |
Why?
| | Enterovirus Infections | 2 | 2016 | 177 | 0.190 |
Why?
| | Hospitalization | 4 | 2019 | 2184 | 0.180 |
Why?
| | Primary Graft Dysfunction | 1 | 2020 | 30 | 0.170 |
Why?
| | Laboratories | 1 | 2021 | 112 | 0.160 |
Why?
| | Carrier State | 2 | 2017 | 67 | 0.160 |
Why?
| | Pediatrics | 2 | 2019 | 1094 | 0.160 |
Why?
| | Pneumococcal Vaccines | 1 | 2021 | 142 | 0.160 |
Why?
| | Opportunistic Infections | 1 | 2019 | 45 | 0.160 |
Why?
| | Advisory Committees | 1 | 2020 | 219 | 0.150 |
Why?
| | Infection Control | 2 | 2017 | 166 | 0.150 |
Why?
| | Communicable Diseases | 1 | 2021 | 159 | 0.150 |
Why?
| | Postoperative Care | 1 | 2020 | 261 | 0.150 |
Why?
| | Transplant Recipients | 1 | 2020 | 179 | 0.150 |
Why?
| | Mucositis | 1 | 2018 | 19 | 0.140 |
Why?
| | Adolescent | 9 | 2022 | 21385 | 0.140 |
Why?
| | Hospital Costs | 1 | 2019 | 116 | 0.140 |
Why?
| | Respiration, Artificial | 1 | 2022 | 642 | 0.140 |
Why?
| | Triazoles | 1 | 2018 | 147 | 0.130 |
Why?
| | Cytomegalovirus Retinitis | 1 | 2016 | 21 | 0.130 |
Why?
| | Vaccines, Inactivated | 1 | 2016 | 68 | 0.130 |
Why?
| | Costs and Cost Analysis | 1 | 2017 | 206 | 0.120 |
Why?
| | Societies, Medical | 1 | 2020 | 817 | 0.120 |
Why?
| | Graft vs Host Disease | 1 | 2018 | 248 | 0.120 |
Why?
| | Polymerase Chain Reaction | 2 | 2016 | 1059 | 0.120 |
Why?
| | Cytomegalovirus | 1 | 2016 | 157 | 0.120 |
Why?
| | Humans | 25 | 2023 | 136803 | 0.120 |
Why?
| | Nasopharynx | 1 | 2015 | 76 | 0.120 |
Why?
| | Enterovirus D, Human | 1 | 2016 | 85 | 0.120 |
Why?
| | DNA, Viral | 1 | 2016 | 363 | 0.110 |
Why?
| | Colorado | 7 | 2021 | 4515 | 0.110 |
Why?
| | Immunosuppressive Agents | 1 | 2019 | 889 | 0.110 |
Why?
| | Immunoglobulin A | 1 | 2015 | 210 | 0.110 |
Why?
| | Male | 14 | 2019 | 67330 | 0.110 |
Why?
| | Vaccines | 1 | 2019 | 405 | 0.110 |
Why?
| | Guanine Nucleotide Exchange Factors | 1 | 2014 | 66 | 0.100 |
Why?
| | Internship and Residency | 1 | 2023 | 1133 | 0.100 |
Why?
| | Retrospective Studies | 11 | 2022 | 15510 | 0.100 |
Why?
| | Cerebrovascular Disorders | 1 | 2014 | 96 | 0.100 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 851 | 0.100 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 250 | 0.100 |
Why?
| | Immunologic Memory | 1 | 2015 | 370 | 0.100 |
Why?
| | Picornaviridae Infections | 1 | 2012 | 47 | 0.100 |
Why?
| | Mass Screening | 2 | 2017 | 1267 | 0.090 |
Why?
| | Herpesvirus 3, Human | 1 | 2014 | 332 | 0.080 |
Why?
| | Herpes Zoster | 1 | 2014 | 316 | 0.080 |
Why?
| | Young Adult | 2 | 2015 | 13129 | 0.070 |
Why?
| | Female | 11 | 2019 | 72816 | 0.070 |
Why?
| | Pandemics | 2 | 2020 | 1616 | 0.070 |
Why?
| | Nervous System Diseases | 1 | 2010 | 263 | 0.070 |
Why?
| | Prognosis | 1 | 2016 | 4013 | 0.070 |
Why?
| | Adult | 5 | 2021 | 37643 | 0.070 |
Why?
| | Cytokines | 1 | 2015 | 2084 | 0.070 |
Why?
| | Papillomavirus Vaccines | 1 | 2010 | 237 | 0.070 |
Why?
| | Cost-Benefit Analysis | 2 | 2019 | 587 | 0.060 |
Why?
| | Infectious Disease Medicine | 1 | 2023 | 13 | 0.050 |
Why?
| | Accreditation | 1 | 2023 | 82 | 0.050 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2010 | 1322 | 0.050 |
Why?
| | Parents | 1 | 2010 | 1340 | 0.050 |
Why?
| | Incidence | 2 | 2019 | 2797 | 0.040 |
Why?
| | Microbiology | 1 | 2021 | 24 | 0.040 |
Why?
| | Immunization, Secondary | 1 | 2021 | 89 | 0.040 |
Why?
| | Staining and Labeling | 1 | 2021 | 148 | 0.040 |
Why?
| | Critical Pathways | 1 | 2020 | 88 | 0.040 |
Why?
| | Consensus | 1 | 2022 | 678 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2020 | 5106 | 0.040 |
Why?
| | United States | 3 | 2021 | 14691 | 0.040 |
Why?
| | Information Dissemination | 1 | 2020 | 215 | 0.040 |
Why?
| | Needs Assessment | 1 | 2020 | 372 | 0.040 |
Why?
| | Age Factors | 2 | 2019 | 3286 | 0.040 |
Why?
| | Interprofessional Relations | 1 | 2020 | 281 | 0.040 |
Why?
| | Morbidity | 1 | 2019 | 323 | 0.040 |
Why?
| | Models, Econometric | 1 | 2017 | 34 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2018 | 155 | 0.030 |
Why?
| | Allografts | 1 | 2018 | 146 | 0.030 |
Why?
| | Quality-Adjusted Life Years | 1 | 2017 | 113 | 0.030 |
Why?
| | Markov Chains | 1 | 2017 | 123 | 0.030 |
Why?
| | Patient Isolation | 1 | 2017 | 19 | 0.030 |
Why?
| | Ophthalmoscopy | 1 | 2016 | 36 | 0.030 |
Why?
| | Epidemiological Monitoring | 1 | 2017 | 60 | 0.030 |
Why?
| | Bacteriological Techniques | 1 | 2017 | 73 | 0.030 |
Why?
| | Program Evaluation | 1 | 2020 | 889 | 0.030 |
Why?
| | Clinical Competence | 1 | 2023 | 1094 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2018 | 209 | 0.030 |
Why?
| | North America | 1 | 2016 | 312 | 0.030 |
Why?
| | Transplantation, Homologous | 1 | 2016 | 415 | 0.030 |
Why?
| | Disease Progression | 1 | 2022 | 2751 | 0.030 |
Why?
| | Viral Load | 1 | 2016 | 464 | 0.030 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2016 | 233 | 0.030 |
Why?
| | Hematologic Neoplasms | 1 | 2016 | 155 | 0.030 |
Why?
| | Cost of Illness | 1 | 2016 | 302 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1964 | 0.030 |
Why?
| | Antibodies, Neutralizing | 1 | 2016 | 285 | 0.030 |
Why?
| | Disease Outbreaks | 1 | 2016 | 386 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2014 | 399 | 0.020 |
Why?
| | Rhinovirus | 1 | 2012 | 58 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2022 | 1798 | 0.020 |
Why?
| | Quality Improvement | 1 | 2020 | 1163 | 0.020 |
Why?
| | Enterovirus | 1 | 2012 | 86 | 0.020 |
Why?
| | Risk Factors | 2 | 2019 | 10332 | 0.020 |
Why?
| | Logistic Models | 1 | 2016 | 2067 | 0.020 |
Why?
| | Inpatients | 1 | 2015 | 496 | 0.020 |
Why?
| | Critical Illness | 1 | 2016 | 804 | 0.020 |
Why?
| | Los Angeles | 1 | 2010 | 76 | 0.020 |
Why?
| | Parental Consent | 1 | 2010 | 25 | 0.020 |
Why?
| | Infant | 2 | 2016 | 9395 | 0.020 |
Why?
| | Cohort Studies | 2 | 2010 | 5704 | 0.020 |
Why?
| | Risk Assessment | 1 | 2019 | 3434 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2016 | 2822 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2021 | 5744 | 0.020 |
Why?
| | Seasons | 1 | 2010 | 544 | 0.020 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2010 | 254 | 0.020 |
Why?
| | Papillomavirus Infections | 1 | 2010 | 324 | 0.020 |
Why?
| | Oxygen | 1 | 2010 | 930 | 0.020 |
Why?
| | Prevalence | 1 | 2012 | 2710 | 0.020 |
Why?
| | Critical Care | 1 | 2010 | 583 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 5424 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2016 | 6032 | 0.010 |
Why?
| | Antiviral Agents | 1 | 2010 | 739 | 0.010 |
Why?
| | Time Factors | 1 | 2015 | 6809 | 0.010 |
Why?
| | Patient Acceptance of Health Care | 1 | 2010 | 805 | 0.010 |
Why?
| | Mutation | 1 | 2014 | 3947 | 0.010 |
Why?
| | Middle Aged | 2 | 2016 | 33239 | 0.010 |
Why?
| | Brain | 1 | 2014 | 2664 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3556 | 0.010 |
Why?
| | Aged | 1 | 2010 | 23808 | 0.010 |
Why?
|
|
Curtis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|